X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare GSK Pharma with VENUS REMEDIES - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

GSK PHARMA vs VENUS REMEDIES - Comparison Results

GSK PHARMA    Change

GSK Pharma is one of the leading MNC pharma companies in the Indian market. It is a 50.7% subsidiary of GlaxoSmithKline Plc, one of the world's largest pharma companies. GSK Pharma's product portfolio boasts of some of the leading brands like Augment... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    GSK PHARMA VENUS REMEDIES GSK PHARMA/
VENUS REMEDIES
 
P/E (TTM) x 66.9 -9.0 - View Chart
P/BV x 11.7 0.1 8,380.4% View Chart
Dividend Yield % 1.1 0.0 -  

Financials

 GSK PHARMA   VENUS REMEDIES
EQUITY SHARE DATA
    GSK PHARMA
Mar-17
VENUS REMEDIES
Mar-17
GSK PHARMA/
VENUS REMEDIES
5-Yr Chart
Click to enlarge
High Rs3,838143 2,687.7%   
Low Rs2,63765 4,056.9%   
Sales per share (Unadj.) Rs354.2324.2 109.3%  
Earnings per share (Unadj.) Rs39.86.4 620.3%  
Cash flow per share (Unadj.) Rs42.940.6 105.7%  
Dividends per share (Unadj.) Rs30.000-  
Dividend yield (eoy) %0.90-  
Book value per share (Unadj.) Rs236.9366.0 64.7%  
Shares outstanding (eoy) m84.7012.34 686.4%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x9.10.3 2,852.0%   
Avg P/E ratio x81.416.2 502.3%  
P/CF ratio (eoy) x75.52.6 2,949.3%  
Price / Book Value ratio x13.70.3 4,812.8%  
Dividend payout %75.40-   
Avg Mkt Cap Rs m274,2161,282 21,387.6%   
No. of employees `0004.70.9 520.2%   
Total wages/salary Rs m4,830251 1,924.3%   
Avg. sales/employee Rs Th6,387.04,430.1 144.2%   
Avg. wages/employee Rs Th1,028.3278.0 369.9%   
Avg. net profit/employee Rs Th717.187.6 818.6%   
INCOME DATA
Net Sales Rs m30,0004,000 749.9%  
Other income Rs m72823 3,208.0%   
Total revenues Rs m30,7284,023 763.8%   
Gross profit Rs m4,190785 533.9%  
Depreciation Rs m263422 62.4%   
Interest Rs m0344 0.0%   
Profit before tax Rs m4,65542 11,057.0%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m4570-   
Tax Rs m1,744-37 -4,713.5%   
Profit after tax Rs m3,36879 4,257.9%  
Gross profit margin %14.019.6 71.2%  
Effective tax rate %37.5-87.9 -42.6%   
Net profit margin %11.22.0 567.8%  
BALANCE SHEET DATA
Current assets Rs m16,7422,606 642.4%   
Current liabilities Rs m7,2021,980 363.7%   
Net working cap to sales %31.815.6 203.2%  
Current ratio x2.31.3 176.6%  
Inventory Days Days52128 40.4%  
Debtors Days Days2143 48.2%  
Net fixed assets Rs m8,6355,353 161.3%   
Share capital Rs m847123 686.4%   
"Free" reserves Rs m19,2224,393 437.6%   
Net worth Rs m20,0694,516 444.4%   
Long term debt Rs m101,618 0.6%   
Total assets Rs m30,0388,291 362.3%  
Interest coverage xNM1.1-  
Debt to equity ratio x00.4 0.1%  
Sales to assets ratio x1.00.5 207.0%   
Return on assets %11.25.1 219.9%  
Return on equity %16.81.8 958.1%  
Return on capital %25.56.3 404.8%  
Exports to sales %00-   
Imports to sales %018.4 0.0%   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNA736 0.0%   
Fx inflow Rs m5280-   
Fx outflow Rs m7,193736 976.9%   
Net fx Rs m-6,665-736 905.2%   
CASH FLOW
From Operations Rs m2,360997 236.7%  
From Investments Rs m3,008-461 -652.1%  
From Financial Activity Rs m-5,108-571 894.5%  
Net Cashflow Rs m260-35 -741.6%  

Share Holding

Indian Promoters % 0.0 32.9 -  
Foreign collaborators % 50.7 0.0 -  
Indian inst/Mut Fund % 10.2 0.2 5,666.7%  
FIIs % 23.8 0.6 4,103.4%  
ADR/GDR % 0.0 0.0 -  
Free float % 15.4 66.4 23.2%  
Shareholders   102,036 20,121 507.1%  
Pledged promoter(s) holding % 0.0 36.4 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare GSK PHARMA With:   DIVIS LABORATORIES  WOCKHARDT LTD.  SUN PHARMA  FRESENIUS KABI ONCO.  FDC LTD.  

Compare GSK PHARMA With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends Volatile Day in Red; Pharma Stocks Lose Most(Closing)

After opening the day in green, share markets in India witnessed volatile trading activity throughout the day and ended the day on a negative note.

Related Views on News

VENUS REMEDIES Announces Quarterly Results (4QFY18); Net Profit Down 307.2%

Jun 12, 2018 | Updated on Jun 12, 2018

For the quarter ended March 2018, VENUS REMEDIES has posted a net profit of Rs 94 m (down 307.2% YoY). Sales on the other hand came in at Rs 932 m (up 16.8% YoY). Read on for a complete analysis of VENUS REMEDIES's quarterly results.

GSK PHARMA Announces Quarterly Results (4QFY18); Net Profit Down 6.4%

May 28, 2018 | Updated on May 28, 2018

For the quarter ended March 2018, GSK PHARMA has posted a net profit of Rs 1 bn (down 6.4% YoY). Sales on the other hand came in at Rs 7 bn (down 4.5% YoY). Read on for a complete analysis of GSK PHARMA's quarterly results.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

More Views on News

Most Popular

After Vakrangee and Manpasand, More Auditors May Soon Resign. To Protect Your Wealth, Avoid these Stocks(The 5 Minute Wrapup)

Jun 8, 2018

The change in auditing regulations can bring a big change in corporate governance behaviour in the mid and small-cap space.

Alert: Pharma Stocks Are About to Shoot Up - And a Superb Stock for Trading(Profit Hunter)

Jun 13, 2018

The ailing pharma stocks are bouncing back to health. Read this to find out the best way to profit from them.

GST Will Not Solve Problem of High Prices of Petrol and Diesel(Vivek Kaul's Diary)

Jun 13, 2018

Though it will bring transparency in their pricing and that in itself will be a welcome move.

Has the Market Bottomed Out?(Sector Info)

Jun 11, 2018

The yield spread is an effective barometer that can indicate the direction the markets are headed.

Is Data Pointing Towards a Revival in the FMCG Sector?(Sector Info)

Jun 8, 2018

After several quarters of stress in the aftermath of demonetisation and the rollout of GST, this data is pointing towards revival in the India's rural FMCG industry.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

GSK PHARMA SHARE PRICE


Jun 21, 2018 (Close)

TRACK GSK PHARMA

  • Track your investment in GSK PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

COMPARE GSK PHARMA WITH

MARKET STATS